Taking a patient-first, precision medicine approach to orphan drug development

Epygenix Therapeutics is a precision medicine biotech company developing drugs to treat Dravet syndrome and other rare forms of genetic epilepsy. Recognizing the unmet needs of patients with these diseases, Epygenix has adopted a drug-repurposing strategy intended to accelerate research and development, and is approaching the start of a phase 1/2 trial of its lead candidate.

Like Comment
Page of
Go to the profile of Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.

No comments yet.